Location of Repository

Update on first-line treatment of advanced ovarian carcinoma

By Kemp Z and Ledermann JA

Abstract

Z Kemp,1 JA Ledermann1,21Department of Oncology, University College London Hospitals, 2University College London Cancer Institute, University College London, London, United KingdomAbstract: Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.Keywords: ovarian cancer, first-line therapy, neoadjuvant, intraperitoneal, dose-dense, angiogenesi

Topics: Gynecology and obstetrics, RG1-991, Medicine, R, DOAJ:Gynecology and Obstetrics, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Dove Medical Press
Year: 2013
OAI identifier: oai:doaj.org/article:d0c953adc1a64d95aecdd5e7128700d2
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1179-1411 (external link)
  • http://www.dovepress.com/updat... (external link)
  • https://doaj.org/article/d0c95... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.